Transforming the Treatment of Neuromuscular Diseases

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.

Creating the new generation of genetic therapies

Learn more about our pioneering Science

Advancing revolutionary therapies to treat degenerative neuromuscular diseases

Learn more about our emerging Pipeline

Careers at PepGen

Seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases

Learn more about Working at PepGen

Latest Updates

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

– Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls – David Pelissier, CPA, will serve as Vice President of Finance – New leaders will support PepGen in establishing its U.S. presence, building its financial strategy and advancing its pipeline BOSTON and…

PepGen to Present at Stifel’s 3rd Annual CNS Day

Boston, Mass. and Oxford, UK (March 23, 2021) – PepGen, Inc. a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur, CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference. The presentation is scheduled for Wednesday, March 31,…

PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference

EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes; advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 Boston, Mass. and Oxford, UK (March 15, 2021) – PepGen, an emerging biotechnology company focused on developing transformative therapies for…